Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0Y1FO
|
||||
| Former ID |
DIB008120
|
||||
| Drug Name |
Rubitecan
|
||||
| Synonyms |
Inhaled Orathecin; L9NC; Rubitecan (inhaled); Aerosolized liposomal 9 nitro-20 (S) camptothecin; Rubitecan (inhaled), SuperGen; 9-Nitro-20(S)-camptothecin
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Human immunodeficiency virus infection [ICD9: 279.3; ICD10:B20-B26] | Phase 3 | [1] | ||
| Company |
SuperGen; Clayton Foundation For Research; MD Anderson Cancer Center
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C20H15N3O6
|
||||
| Canonical SMILES |
n12c(c3c(C2)cc2c([N+](=O)[O-])cccc2n3)cc2c(c1=O)COC(=O)<br />[C@]2(O)CC
|
||||
| CAS Number |
CAS 91421-42-0
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Toposisomerase-1 | Target Info | Inhibitor | [2] | |
| NetPath Pathway | IL2 Signaling Pathway | ||||
| PANTHER Pathway | DNA replication | ||||
| Pathway Interaction Database | Caspase Cascade in Apoptosis | ||||
| WikiPathways | Integrated Pancreatic Cancer Pathway | ||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT00005869) Nitrocamptothecin Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer. U.S. National Institutes of Health. | ||||
| REF 2 | Rubitecan. Expert Opin Investig Drugs. 2006 Jan;15(1):71-9. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.